A Year After It Wins Ratiopharm, Teva Reaps Rewards in Europe
Executive Summary
For innovator firms, Europe has been about surviving multiple price cuts and government austerity measures. For generics firms, it has become a land of opportunity, where 2011 growth will outpace the overall pharmaceutical market.
You may also be interested in...
Teva CEO Offers Small Insights Into Big Priorities As Run Up to Dec. 11
Teva CEO Jeremy Levin provided additional glimpses of the company’s new strategy on a Q3 earnings call in advance of an investor meeting on Dec. 11, where he and Teva management will reveal their full agenda. Levin again put the emphasis on “focus” and “discipline” over “pure growth,” confirmed the company’s ‘confidence in the MS drug laquinimod, and highlighted several senior management appointments that reflect Teva’s new priorities.
Lipitor Will Fade, Not Fall Off The Patent Cliff In Europe
Lipitor's European sales won't all disappear overnight, But the strong post-patent performance in Spain isunlikely to be replicated either.
Lipitor Will Fade, Not Fall Off The Patent Cliff In Europe
Lipitor's European sales won't all disappear overnight, But the strong post-patent performance in Spain isunlikely to be replicated either.